You are here

Neuroscience

AbbVie to buy Cerevel in $8.7B bet on brain drugs

AbbVie to buy Cerevel in $8.7B bet on brain drugs

BioPharma Dive

Cerevel Therapeutics

Flag link:

As J&J outlines bullish pipeline goals, neuroscience pipeline takes a starring role

As J&J outlines bullish pipeline goals, neuroscience pipeline takes a starring role

Fierce Biotech

major depressive disorder

Flag link:

Immuneering takes aim at cancer’s ‘superhighway’

Immuneering takes aim at cancer’s ‘superhighway’

Pharma Voice

Flag link:

2 Things About AbbVie That Investors Are Ignoring

2 Things About AbbVie That Investors Are Ignoring

Motley Fool

Flag link:

Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas

Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas

BioSpace

cardiovascular disease

Flag link:

J&J-backed startup launches with $100M to build better brain drugs

J&J-backed startup launches with $100M to build better brain drugs

BioPharma Dive

Rapport Therapeutics

neurological disorders

Flag link:

AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer's and depression prospect

AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer's and depression prospect

Fierce Biotech

Syndesi Therapeutics

Alzheimer's disease

Flag link:

Roche Signs Machine-Learning Neuroscience Deal With Recursion

Roche Signs Machine-Learning Neuroscience Deal With Recursion

Bloomberg

artificial intelligence

machine learnings

Recursion Pharmaceuticals

Flag link:

Lilly, with Alzheimer's in its crosshairs, forms new neuroscience unit, unifies oncology under Loxo exec

Lilly, with Alzheimer's in its crosshairs, forms new neuroscience unit, unifies oncology under Loxo exec

Fierce Biotech

Alzheimer's disease

Flag link:

Genentech teams with academics for 10-year neuroscience R&D push

Genentech teams with academics for 10-year neuroscience R&D push

Fierce Biotech

Flag link:

5 trends in biotech dealmaking to watch in 2021

5 trends in biotech dealmaking to watch in 2021

BioPharma Dive

Flag link:

Novartis acquires a small biotech and its trio of brain drugs

Novartis acquires a small biotech and its trio of brain drugs

BioPharma Dive

Flag link:

Roche shelved these psychiatry drugs. So its former head of neuro cooked up some new plans — and raised $59M for his startup

Roche shelved these psychiatry drugs. So its former head of neuro cooked up some new plans — and raised $59M for his startup

Endpoints

Flag link:

Big pharma backed away from brain drugs. Is a return in sight?

Big pharma backed away from brain drugs. Is a return in sight?

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Biogen Teams Up With Startup CAMP4 to Scout for New Neuro Drugs

Biogen Teams Up With Startup CAMP4 to Scout for New Neuro Drugs

Xconomy

CAMP4 Therapeutics

drug development

Flag link:

Is there a future for pharma in neuro?

Is there a future for pharma in neuro?

Fierce Biotech

Flag link:

Amgen to cut 149 staff in retreat from neuroscience R&D

Amgen to cut 149 staff in retreat from neuroscience R&D

Fierce Biotech

Flag link:

As Amgen zeroes in on cancer, neuroscience pipeline under the ax

As Amgen zeroes in on cancer, neuroscience pipeline under the ax

Fierce Biotech

Flag link:

U.S. Travel Ban Disrupts The World's Largest Brain Science Meeting

U.S. Travel Ban Disrupts The World's Largest Brain Science Meeting

NPR

Society for Neuroscience

Flag link:

Charles River 'reaffirms' commitment to tough neuroscience beat

Charles River 'reaffirms' commitment to tough neuroscience beat

Fierce Biotech

Charles River Laboratories

Alzheimer's disease

Flag link:

Pages